YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale

Nicole Eter,Rishi P. Singh,Francis Abreu,Kemal Asik,Karen Basu,Caroline Baumal,Andrew Chang,Karl G. Csaky,Zdenka Haskova,Hugh Lin,Carlos Quezada Ruiz,Paisan Ruamviboonsuk,David Silverman,Charles C. Wykoff,Jeffrey R. Willis

Ophthalmology Science（2022）

引用 9|浏览11

暂无评分

摘要

YOSEMITE and RHINE were the first registrational trials in retinal disease to incorporate an objective PTI regimen, allowing for up to every-16-week adjustable dosing with a dual angiopoietin-2 and VEGF-A inhibitor, faricimab 6.0 mg, for treatment of DME.

查看译文

关键词

Adjustable dosing,Angiopoietin-2,Anti–vascular endothelial growth factor,Bispecific antibody,Diabetic macular edema,Faricimab,Personalized treatment interval,Phase 3 clinical trial design

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要